CD274 and lip and oral cavity carcinoma: In this study, we investigated whether anti-PD-L1 mAbs are advantageous for the treatment of oral cancers by ADCC/CDC activities, rather than by neutralization of PD-L1/PD1 interaction, as human PD-L1 does not react with mouse PD-1.